{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:32:19Z","timestamp":1791725539445,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd001155.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000}}],"reference-count":266,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001155.pub3","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:40:29Z","timestamp":1737960029000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women"],"prefix":"10.1002","volume":"2025","author":[{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health; University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ching","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Center; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit; Ottawa Civic Hospital \/ Loeb Research Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Zheng","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E","family":"Kelly","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Community Medicine; University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine; University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0001|cit1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001155.pub2","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guideline 26: informative statements communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0003|cit3","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from www.training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporosis International"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub3-BIB0005|cit5","first-page":"1426","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman","year":"2002","journal-title":"Canadian Medical Association Journal"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD001155.pub3-BIB0007|cit7","first-page":"S1","article-title":"2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0008|cit8","unstructured":"World Health Organization WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report Available at: http:\/\/www.who.int\/chp\/topics\/Osteoporosis.pdf"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0009|cit9","unstructured":"World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group World Health Organisation Technology Report Series: 843. 1994 1 129"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Archives of Osteoporosis"},{"issue":"1-2","key":"10.1002\/14651858.CD001155.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","article-title":"SCOPE: a scorecard for osteoporosis in Europe","volume":"8","author":"Kanis","year":"2013","journal-title":"Archives of Osteoporosis"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1359\/jbmr.090319","article-title":"Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD","volume":"24","author":"Langsetmo","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women","volume":"149","author":"Cummings","year":"1989","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00198-012-2225-1","article-title":"Long-term mortality following fractures at different skeletal sites: a population-based cohort study","volume":"24","author":"Melton","year":"2013","journal-title":"Osteoporosis International"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporosis International"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/jbmr.3118","article-title":"Population-wide impact of non-hip non-vertebral fractures on mortality","volume":"32","author":"Tran","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The population burden of fractures originates in women with osteopenia, not osteoporosis","volume":"17","author":"Pasco","year":"2006","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1210\/jc.2004-1568","article-title":"Hip fracture in women without osteoporosis","volume":"90","author":"Wainwright","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1385\/JCD:4:4:373","article-title":"Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis","volume":"4","author":"Greenspan","year":"2001","journal-title":"Journal of Clinical Densitometry"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Compston J Cooper A Cooper C Gittoes N Gregson C Harvey N et al; National Osteoporosis Guideline Group (NOGG) NOGG 2017: UK clinical guideline for the prevention and treatment of osteoporosis Archives of Osteoporosis 2017 12 1 43 10.1007\/s11657-017-0324-5","DOI":"10.1007\/s11657-017-0324-5"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0024|cit24","unstructured":"FDA Drug Approval Package-Fosamax; Alendronate Sodium Tablets Application Number: NDA 020560; 29 September 1995 Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/020560Orig1s000rev.pdf"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocrine Reviews"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001155.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/BF01623001","article-title":"Preclinical pharmacology of alendronate","volume":"3","author":"Rodan","year":"1993","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2016.10.013","article-title":"Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity","volume":"94","author":"Van der Velde","year":"2017","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0029|cit29","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological Expectations of Cochrane Intervention Reviews Cochrane: London, Version February 2022 https:\/\/methods.cochrane.org\/methodological-expectations-cochrane-intervention-reviews"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/AOG.0000000000004730","article-title":"Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2","volume":"139","author":"The American College of Obstetricians and Gynecologists (ACOG) Committee on Clinical Practice Guidelines\u2013Gynecology","year":"2022","journal-title":"Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.11622\/smedj.2019028","article-title":"Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review","volume":"60","author":"Chandran","year":"2019","journal-title":"Singapore Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jval.2014.01.008","article-title":"Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis","volume":"17","author":"Ellis","year":"2014","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1471-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-non hip fractures in osteoporosis: a network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","journal-title":"Journal of Cell Biochemistry"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0038|cit38","first-page":"658","article-title":"Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis","volume":"17","author":"Migliore","year":"2013","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","article-title":"Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials","volume":"77","author":"Taggart","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"issue":"3-4","key":"10.1002\/14651858.CD001155.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1159\/000453138","article-title":"Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention","volume":"40","author":"Yang","year":"2016","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0042|cit42","first-page":"711","article-title":"Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis","volume":"101","author":"Luckey","year":"2003","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0043|cit43","unstructured":"ICH Harmonized Tripartite Guideline. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Step 4 version https:\/\/database.ich.org\/sites\/default\/files\/E2A_Guideline.pdf"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0044|cit44","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available at: https:\/\/training.cochrane.org\/handbook\/PDF\/v5.2\/chapter-08"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0045|cit45","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1002\/sim.6301","article-title":"The Peto odds ratio viewed as a new effect measure","volume":"33","author":"Brockhaus","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0047|cit47","unstructured":"WebPlotDigitizer Version: 4.2 Rohatgi A Rohatgi A"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"24","key":"10.1002\/14651858.CD001155.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"Journal of the American Medical Association"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial long-term extension (FLEX): A randomised trial","volume":"296","author":"Black","year":"2006","journal-title":"Journal of the American Medical Association"},{"issue":"9041","key":"10.1002\/14651858.CD001155.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. [See comment]","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0055|cit55","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0056|cit56","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from www.training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub3-BIB0058|cit58","first-page":"265","article-title":"Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers","volume":"82","author":"Bone","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s002239900634","article-title":"An open-label extension study of alendronate treatment in elderly women with osteoporosis","volume":"64","author":"Downs","year":"1999","journal-title":"Calcified Tissue International"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut CH","year":"1995","journal-title":"American Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1742-1241.2001.tb11111.x","article-title":"Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis","volume":"55","author":"Dursun","year":"2001","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomised, double-blind, placebo-controlled trial","volume":"136","author":"Greenspan","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","article-title":"Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study","volume":"89","author":"McClung","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"22","key":"10.1002\/14651858.CD001155.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. [See comment]","volume":"333","author":"Liberman","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub3-BIB0067|cit67","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group","volume":"85","author":"Tonino","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","article-title":"Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis","volume":"101","author":"Tucci","year":"1996","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporosis International"},{"issue":"13","key":"10.1002\/14651858.CD001155.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1-34)) with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00774-003-0438-2","article-title":"Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis","volume":"21","author":"Chailurkit","year":"2003","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1210\/jc.2003-030198","article-title":"Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis","volume":"89","author":"Evi\u00f6","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.GME.0000119981.77837.1F","article-title":"Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis","volume":"11","author":"Luckey","year":"2004","journal-title":"Menopause (New York, N.Y.)"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jcem.87.4.8323","article-title":"Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis","volume":"87","author":"Palomba","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s001980070035","article-title":"A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: A randomized controlled trial","volume":"11","author":"Sahota","year":"2000","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","article-title":"Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial)","volume":"255","author":"Sambrook","year":"2004","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clinical and Experimental Research"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/humrep\/15.10.2087","article-title":"Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study","volume":"15","author":"Tira\u015f","year":"2000","journal-title":"Human Reproduction (Oxford, England)"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s001980200048","article-title":"Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study","volume":"13","author":"Gonnelli","year":"2002","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1345\/aph.1E580","article-title":"Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women","volume":"39","author":"Ho","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s0022330001142","article-title":"The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study","volume":"67","author":"Kung","year":"2000","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S8756-3282(00)00378-1","article-title":"Alendronate prevents bone loss in Chinese women with osteoporosis","volume":"27","author":"Lau","year":"2000","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group","volume":"128","author":"McClung","year":"1998","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","article-title":"Alendronate in the prevention of osteoporosis: 7-year follow-up","volume":"15","author":"Sambrook","year":"2004","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S8756-3282(00)00291-X","article-title":"Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis","volume":"27","author":"Rossini","year":"2000","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S8756-3282(03)00082-6","article-title":"Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial","volume":"33","author":"Uusi-Rasi","year":"2003","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S8756-3282(00)00384-7","article-title":"Effects of alendronate on osteopenic postmenopausal Chinese women","volume":"27","author":"Yen","year":"2000","journal-title":"Bone"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1210\/jcem.87.6.8575","article-title":"Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women","volume":"87","author":"Bell","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0095|cit95","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate\/Estrogen Study Group","volume":"85","author":"Bone","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0096|cit96","first-page":"1783","article-title":"Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women","volume":"85","author":"Downs","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial","volume":"289","author":"Greenspan","year":"2003","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0099|cit99","first-page":"1116","article-title":"Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"86","author":"Murphy","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0015-0282(03)00757-X","article-title":"Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women","volume":"80","author":"Davas","year":"2003","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/BMR-2004-17106","article-title":"Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis","volume":"17","author":"Aki","year":"2004","journal-title":"Journal of Back and Musculoskeletal Rehabilitation"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/BMR-2005-183-405","article-title":"Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis","volume":"18","author":"Yildirim","year":"2005","journal-title":"Journal of Back and Musculoskeletal Rehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0104|cit104","unstructured":"Prevention of postmenopausal bone loss in osteopenic women with alendronate given on a 70 mg once-every two week regimen : a 2-year, double-blind, placebo-controlled clinical trial EU Clinical Trials Register Available from https:\/\/www.clinicaltrialsregister.eu\/ctr search\/trial\/2006-005862-38\/BE"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0105|cit105","unstructured":"Comparative study of zoledronic acid and alendronate in the treatment of postmenopausal osteoporosis https:\/\/login.proxy.bib.uottawa.ca\/login?url=http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=cctr&AN=CN-02439140 2021"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0106|cit106","unstructured":"Prospective, randomized, multicenter study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and \/ or aggravation of previous vertebral fractures in women with clinical vertebral fracture or recent hip fracture (imminent risk of fracture) and low bone mineral density https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005712-22\/ES 2021"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0107|cit107","unstructured":"Comparative antiresorptive efficacy discontinuation of denosumab https:\/\/clinicaltrials.gov\/show\/NCT03623633"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0108|cit108","unstructured":"Novel precision medicine approach to treatment of osteoporosis based on bone turnover https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05151484"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0109|cit109","unstructured":"A multi center, randomized, open-label, parallel, phase IV clinical trial to evaluate efficacy and safety of MASI BONE s (alendronate sodium trihydrate) in postmenopausal women with osteoporosis https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05387200"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0110|cit110","unstructured":"The effectiveness of single or repeat zoledronate infusion versus oral alendronate in consolidating the bone accrual achieved with denosumab: a study organised by the European calcified tissue society https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05575167"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD001155.pub3-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1007\/s00198-020-05696-3","article-title":"Comparative study of weekly alendronate vs. yearly zoledronic acid injection in treatment of postmenopausal osteoporosis in terms of efficacy, compliance and bone markers estimation","volume":"31","author":"Chawla","year":"2020","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0112|cit112","unstructured":"Concise, accurate diagnosis and treatment eveluation of osteoporosis patients using new imaging techniques http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-IPR-16009416 2016"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001155.pub3-BIB0113|cit113","first-page":"S432","article-title":"Application of quantitative bone scan using kbonevaluesforthe assessmentofregional bone metabolism in postmenopausal osteoporotic women treated either with alendronate or teriparatide","volume":"Conference:","author":"Dixit","year":"2019","journal-title":"Osteoporos.Int."},{"key":"10.1002\/14651858.CD001155.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.bonr.2020.100737","article-title":"Effects of bendroflumethiazide on bone mineral density; results from the BONATHIAD randomized double-blind placebo-controlled cohort study","volume":"13","author":"Emmanuel","year":"2020","journal-title":"Bone Report"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0115|cit115","unstructured":"A Phase II, randomized, double-blind, parallel group study to examine bone quality and bone mineral density changes following treatment with SB-462795 (40mg, 80mg, 120mg or 160mg), alendronate or placebo in postmenopausal women with osteoporosis https:\/\/ictrptest.azurewebsites.net\/Trial2.aspx?TrialID=EUCTR2006-000635-94-GB 2006"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/21514593211058764","article-title":"Regional bone metabolism in postmenopausal osteoporotic women treated with either alendronate or teriparatide","volume":"12","author":"Garg","year":"2021","journal-title":"Geriatric Orthopaedic Surgery and Rehabilitation"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1470320320928874","article-title":"Effects of anti-osteoporosis therapy on plasma aldosterone and renin","volume":"21","author":"Hu","year":"2020","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System: JRAAS"},{"issue":"596","key":"10.1002\/14651858.CD001155.pub3-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"783","DOI":"10.22122\/jims.v38i596.13293","article-title":"The findings of bone mineral densitometry following preventive treatment with alendronate in menopausal women with osteopenia: What is the best dose?. [Persian]","volume":"38","author":"Karimifar","year":"2020","journal-title":"Journal of Isfahan Medical School"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub3-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11657-022-01131-8","article-title":"Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study","volume":"17","author":"Li","year":"2022","journal-title":"Archives of Osteoporosis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001155.pub3-BIB0120|cit120","first-page":"S724","article-title":"Comparative study of weekly alendronate vs. yearly zoledronic acid injectionint reatment of postmenopausal osteoporosis in terms of efficacy, compliance and bone markers estimation","volume":"Conference:","author":"Malhotra","year":"2019","journal-title":"Osteoporos.Int."},{"key":"10.1002\/14651858.CD001155.pub3-BIB0121|cit121","unstructured":"Low-dose hormone replacement therapy and alendronate for osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT00000430"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0122|cit122","unstructured":"Vitamin K as additive treatment in osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT01232647"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0123|cit123","unstructured":"Efficacy and safety of odanacatib in postmenopausal women previously treated with alendronate (MK-0822-050) https:\/\/clinicaltrials.gov\/show\/NCT01552122"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub3-BIB0124|cit124","first-page":"1","article-title":"Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial","volume":"4","author":"Ones","year":"2006","journal-title":"Internet Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0125|cit125","first-page":"1","article-title":"Effectiveness of a single zoledronic acid infusion vs weekly oral alendronate in the treatment of postmenopausal osteoporosis: a prospective study","volume":"26","author":"Singh","year":"2021","journal-title":"JK Practitioner"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00774-019-01074-0","article-title":"Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05)","volume":"38","author":"Tanaka","year":"2020","journal-title":"Journal of Bone Mineral and Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub3-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","article-title":"A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05","volume":"32","author":"Hagino","year":"2021","journal-title":"Osteoporosis International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001155.pub3-BIB0128|cit128","first-page":"S113","article-title":"Beneficial effects of strontium ranelate compared to alendronate on bone mass and strength parameters at the tibia in postmenopausal osteoporotic women: A 2-year study","volume":"23","author":"Felsenberg","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0129|cit129","unstructured":"Clinical Study Report Synopsis A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2g per day of strontium ranelate versus alendronate 70mg per week in women with postmenopausal osteoporosis on bone geometry and bone strength measured by peripheral Quantitative Computed Tomography (p-QCT) Institut de Recherches Internationales Servier (I.R.I.S.)"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0131|cit131","unstructured":"Romosozumab (AMG 785) in postmenopausal women with low bone mineral density https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00896532"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1185\/03007995.2011.580341","article-title":"Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: The Japanese Osteoporosis Intervention Trial (JOINT)-02","volume":"27","author":"Orimo","year":"2011","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/bimj.201800038","article-title":"Simple methods for the estimation and sensitivity analysis of principal strata effects using marginal structural models: Application to a bone fracture prevention trial","volume":"61","author":"Uemura","year":"2019","journal-title":"Biometrical Journal"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence PreferenceSatisfaction) study: a 24-month, randomised, cross-over comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","article-title":"Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate","volume":"22","author":"Kendler","year":"2011","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0136|cit136","first-page":"S138","article-title":"Comparison of change in bone resorption and bone mineral density with once weekly alendronate and daily strontium ranelate: A randomised, placebo-controlled study","volume":"23","author":"Lunar","year":"2012","journal-title":"Osteoporosis International"},{"issue":"S1","key":"10.1002\/14651858.CD001155.pub3-BIB0137|cit137","first-page":"S444","article-title":"Lycopene supplementation improved the response of postmenopausal women with osteoporosis to alendronate therapy: A 12-month follow-up study","volume":"28","author":"Ardawi","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0138|cit138","first-page":"34","article-title":"Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass","volume":"11","author":"Felsenberg","year":"2011","journal-title":"Journal of Musculoskeletal Neuronal Interactions"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0139|cit139","unstructured":"A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2g per day of strontium ranelate versus alendronate 70mg per week in women with postmenopausal osteoporosis on bone geometry and bone strength measured by peripheral Quantitative Computed Tomography (p-QCT) INSTITUT de RECHERCHES INTERNATIONALES SERVIER (I.R.I.S.): Clinical Study Report Synopsis Protocol code: CL3-12911-030"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0140|cit140","first-page":"8","article-title":"Association between geranylgeranyl pyrophosphate synthase gene polymorphisms and bone phenotypes and response to alendronate treatment in Chinese osteoporotic women","volume":"31","author":"Han","year":"2016","journal-title":"Chung-kuo I Hsueh k'O Hsueh Tsa Chih [Chinese Medical Sciences Journal]"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijgo.2005.06.026","article-title":"Cyclical alendronate treatment in postmenopausal women with osteoporosis","volume":"91","author":"K\u00f6\u015f\u00fc\u015f","year":"2005","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0142|cit142","first-page":"25","article-title":"Adherence to bisphosphonate therapy in postmenopausal osteoporotic women","volume":"53","author":"Kuzmanova","year":"2011","journal-title":"Folia Medica (Plovdiv)"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0143|cit143","first-page":"36","article-title":"Prevention of osteoporotic fractures among high-risk groups of post-menopausal women","volume":"12","author":"Leung","year":"2006","journal-title":"Hong Kong Medical Journal"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0145|cit145","first-page":"97","article-title":"Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study","volume":"8","author":"Muscoso","year":"2004","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"S1","key":"10.1002\/14651858.CD001155.pub3-BIB0146|cit146","first-page":"S111","article-title":"Efficacy of treatment with slow-release sodium fluoride versus alendronate on bone mineral density and fractures in postmenopausal women","volume":"65","author":"Rubin","year":"2017","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0147|cit147","first-page":"139","article-title":"Effectiveness of raloxifene and alendronate combination versus calcium and vitamin D usage: Effects on bone mineral density","volume":"6","author":"T\u00fct\u00fcnc\u00fc","year":"2005","journal-title":"Journal of the Turkish German Gynecology Association"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-6009(91)90129-N","article-title":"Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis","volume":"15","author":"Passeri","year":"1991","journal-title":"Bone and Mineral"},{"issue":"12","key":"10.1002\/14651858.CD001155.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/jbmr.157","article-title":"A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover","volume":"25","author":"Burghardt","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0150|cit150","unstructured":"Alendronate prevents microarchitectural deterioration of trabecular bone in early postmenopausal women Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00504166"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jocd.2013.12.001","article-title":"Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density","volume":"17","author":"Chavez-Valencia","year":"2014","journal-title":"Journal of Clinical Densitometry"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/GME.0000000000000197","article-title":"Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis","volume":"21","author":"Igase","year":"2014","journal-title":"Menopause (New York, N.Y.)"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0153|cit153","first-page":"175","article-title":"Therapeutic equivalence and adherence to treatment with ibandronate 150 mg and alendronate 70 mg in postmenopausal women of concepcion city, Chile","volume":"7","author":"Langenegger","year":"2011","journal-title":"Actualizaciones en Osteologia"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00774-009-0126-y","article-title":"Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study","volume":"28","author":"Li","year":"2010","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/gme.0b013e31825fe2e8","article-title":"Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis","volume":"20","author":"Li","year":"2013","journal-title":"Menopause (New York, N.Y.)"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1749-799X-2-9","article-title":"Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis","volume":"2","author":"Qin","year":"2007","journal-title":"Journal of Orthopaedic Surgery and Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/annrheumdis-2012-eular.3307","article-title":"Comparison of the efficacy of annual zoledronic acid or weekly alendronate. A 3-yr analysis of postmenopausal women with low bone mineral density","volume":"71","author":"Robles-Carranza","year":"2013","journal-title":"Annals of the Rheumatic Disease"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00774-008-0025-7","article-title":"Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women","volume":"27","author":"Sawada","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0165|cit165","first-page":"86","article-title":"The efficacy and safety of Calidron tablets for management of osteoporosis in Jordanian women: A randomised clinical trial","volume":"12","author":"Shilbayeh","year":"2004","journal-title":"Saudi Pharmaceutical Journal"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.metabol.2006.01.008","article-title":"Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women","volume":"55","author":"Tseng","year":"2006","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"56","DOI":"10.6118\/jmm.2017.23.1.56","article-title":"Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women","volume":"23","author":"Um","year":"2017","journal-title":"Journal of Menopausal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00774-009-0057-7","article-title":"The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis","volume":"27","author":"Yan","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/147323001103900133","article-title":"The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in Chinese post-menopausal women at risk of osteoporosis","volume":"39","author":"You","year":"2011","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0170|cit170","first-page":"110","article-title":"The comparison of effectiveness of alendronate and risedronate in osteoporosis treatment. [Turkish] Osteoporoz Tedavisinde Alendronat ve Risedronatin Etkinliklerinin Karsilastirilmasi","volume":"52","author":"Akyol","year":"2006","journal-title":"Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/BF02850205","article-title":"Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis","volume":"23","author":"Atmaca","year":"2006","journal-title":"Advances in Therapy"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1185\/030079907X188035","article-title":"Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density","volume":"23","author":"Bonnick","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0174|cit174","unstructured":"A randomized, double-blind study to compare the efficacy of treatment with denosumab versus alendronate sodium in postmenopausal women with low bone mineral density https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00330460"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00198-015-3392-7","article-title":"A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates","volume":"27","author":"Cosman","year":"2016","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0178|cit178","unstructured":"A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-005581-39\/GB"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0179|cit179","unstructured":"The relationship between osteoporosis and aortic calcification in postmenopausal women https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2008-001865-28"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jbmr.341","article-title":"Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study","volume":"26","author":"Eastell","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.2047","article-title":"Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study","volume":"29","author":"Eastell","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0182|cit182","first-page":"1012","article-title":"A pilot study to assess the efficacy and side effects of silymarin alone and in combination with alendronate in treatment of postmenopausal osteoporosis","volume":"7","author":"El-Hamamsy","year":"2016","journal-title":"International Journal of Pharmaceutical Sciences and Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0183|cit183","first-page":"6893","article-title":"Effects of alendronate sodium versus hormone replacement therapy for osteoporosis","volume":"20","author":"Su","year":"2016","journal-title":"Chinese Journal of Tissue Engineering Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00044011-199815030-00008","article-title":"Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: Two years of continuous treatment","volume":"15","author":"Frediani","year":"1998","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0185|cit185","unstructured":"Efficacy of bisphosphonates in the treatment of postmenopausal osteoporosis Osteoporosis International 2011 22 Suppl 5 S739"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0186|cit186","first-page":"S150","article-title":"Denosumab significantly increases BMD compared with alendronate in postmenopausal women","volume":"26","author":"Galesanu","year":"2015","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s002239900713","article-title":"Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis","volume":"65","author":"Gonnelli","year":"1999","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-011-1583-4","article-title":"Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0189|cit189","unstructured":"Safety\/efficacy of zoledronic acid and alendronate on bone metabolism in postmenopausal women with osteoporosis (ROSE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00404820"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s00198-011-1834-4","article-title":"Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bone.2009.02.016","article-title":"A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis","volume":"44","author":"Hagino","year":"2009","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0192|cit192","unstructured":"A double-blind, multicentric, multinational randomised study to assess the effects of (one year extended to) two years (Amendment No. 4) administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week in women with postmenopausal osteoporosis o bone microarchitecture measured by high resolution peripheral Quantitative Computed Tomography (p-QCT) Institut de Recherches Internationles (I.R.I.S) Clinical Study Report Synopsis Available from https:\/\/v2dis prod.evidencepartners.com\/Generic\/getAttachment2.php?id=651"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3349\/ymj.2005.46.6.750","article-title":"Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis","volume":"46","author":"Iwamoto","year":"2005","journal-title":"Yonsei Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3349\/ymj.2008.49.1.119","article-title":"Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis","volume":"49","author":"Iwamoto","year":"2008","journal-title":"Yonsei Medical Journal"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/annrheumdis-2016-eular.1347","article-title":"A comparison between combination treatment with alendronate and vitamin K and alendronate alone on bone mineral density in patients with postmenopausal osteoporosis? The results of a pilot study","volume":"75","author":"Jokar","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0196|cit196","first-page":"70","article-title":"Comparison of effectiveness of strontium ranelate and alendronate sodium in postmenopausal osteoporosis","volume":"15","author":"Kaya","year":"2009","journal-title":"Osteoporoz Dunyasindan"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0198|cit198","unstructured":"Study of transitioning from alendronate to denosumab https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00377819"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0011-393X(02)80065-0","article-title":"The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial","volume":"63","author":"Kushida","year":"2002","journal-title":"Current Therapeutic Research"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00774-004-0508-0","article-title":"Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study","volume":"22","author":"Kushida","year":"2004","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub3-BIB0201|cit201","first-page":"3076","article-title":"Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial","volume":"84","author":"Lindsay","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalska","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","article-title":"Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study","volume":"24","author":"Miller","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clinthera.2009.04.018","article-title":"Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study","volume":"31","author":"Emkey","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bone.2011.09.035","article-title":"Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease - The DIVINE study","volume":"49","author":"Miller","year":"2011","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/GME.0b013e31827b24af","article-title":"Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial","volume":"20","author":"Min","year":"2013","journal-title":"Menopause (New York, N.Y.)"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijgo.2008.07.011","article-title":"Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis","volume":"103","author":"Nabhan","year":"2008","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporosis International"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-004-1800-5","article-title":"BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial","volume":"16","author":"Palomba","year":"2005","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Medical Science Monitor"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","article-title":"A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-Month results from FACTS-International","volume":"62","author":"Reid","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international","volume":"26","author":"Reid","year":"2006","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0167-4943(96)86998-6","article-title":"The use of bisphosphonates in the treatment of osteoporosis","volume":"22","author":"Russo","year":"1996","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"15","key":"10.1002\/14651858.CD001155.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0217|cit217","unstructured":"Study to determine the efficacy and safety of romosozumab in the treatment of postmenopausal women with osteoporosis (ARCH) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01631214"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/13697137.2010.537408","article-title":"Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis","volume":"14","author":"Sanad","year":"2011","journal-title":"Climacteric"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00296-004-0544-z","article-title":"Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Sarioglu","year":"2006","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0220|cit220","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6062707","article-title":"Effect of traditional Chinese medicine product, qiangguyin, on bone mineral density and bone turnover in Chinese postmenopausal osteoporosis","volume":"2017","author":"Shi","year":"2017","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s001980050214","article-title":"A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis","volume":"10","author":"Shiraki","year":"1999","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/jcpt.12429","article-title":"Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis","volume":"41","author":"Tan","year":"2016","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0223|cit223","first-page":"4","article-title":"The effect of raloxifene, alendronate and risedronate on serum lipid profile in postmenopausal women","volume":"54","author":"Yanik","year":"2008","journal-title":"Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/08860220701260776","article-title":"The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women","volume":"29","author":"Yanik","year":"2007","journal-title":"Renal Failure"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3346\/jkms.2017.32.6.992","article-title":"Effects of combination therapy of alendronate and hormonal therapy on bone mineral density in postmenopausal Korean women: multicenter, randomized controlled clinical trial","volume":"32","author":"Yoon","year":"2017","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s00198-015-3141-y","article-title":"Alendronate sodium\/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension","volume":"26","author":"Zhang","year":"2015","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"116416","DOI":"10.1016\/j.bone.2022.116416","article-title":"Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study","volume":"160","author":"Chiba","year":"2022","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0228|cit228","first-page":"S200","article-title":"Relationships between osteoporosis medication adherence, surrogate marker outcomes and non-vertebral fracture incidence","volume":"47","author":"Eastell","year":"2010","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study: A randomized, controlled trial","volume":"131","author":"Ravn","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1532-5415.2007.01161.x","article-title":"Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial","volume":"55","author":"Barone","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/j.bone.2011.03.511","article-title":"Effects of intravenous zoledronic acid following subcutaneous teriparatide in postmenopausal osteoporosis","volume":"47","author":"Carlino","year":"2011","journal-title":"Bone"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00774-009-0035-0","article-title":"Comparison of the analgesic effects of bisphosphonates: Etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance","volume":"27","author":"Fujita","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0233|cit233","first-page":"571","article-title":"[Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women]","volume":"45","author":"Guan","year":"2010","journal-title":"Zhonghua Fu Chan Ke za Zhi"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1097\/QAD.0b013e3282ef961d","article-title":"Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV","volume":"21","author":"McComsey","year":"2007","journal-title":"AIDS (London, England)"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub3-BIB0235|cit235","first-page":"289","article-title":"Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial","volume":"2","author":"Niimi","year":"2018","journal-title":"Journal of Bone and Mineral Research Plus"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","article-title":"Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)","volume":"27","author":"Ringe","year":"2007","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/mds.20825","article-title":"Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial","volume":"21","author":"Sato","year":"2006","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"e0180325","DOI":"10.1371\/journal.pone.0180325","article-title":"Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax) for osteoporosis treatment","volume":"12","author":"Unnanuntana","year":"2017","journal-title":"PloS One"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.bone.2010.04.481","article-title":"Apparent bone mineral density at femoral neck in the monitoring the early effects of teriparatide","volume":"47","author":"Caffarelli","year":"2010","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0240|cit240","first-page":"S452","article-title":"Effects of combined treatment with alendronate and alfacalcidol comparing with other bisphosphonates and alfacalcidol in BMD changes at postmenopausal osteoporotic women","volume":"27","author":"Galesanu","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00198-006-0157-3","article-title":"Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis","volume":"17","author":"Gonnelli","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13697130801959590","article-title":"Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients","volume":"11","author":"Iizuka","year":"2008","journal-title":"Climacteric"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0243|cit243","first-page":"Suppl 1","article-title":"A randomized trial comparing efficacy and safety of brand versus generic alendronate for osteoporosis treatment","volume":"35","author":"Jarusriwanna","year":"2017","journal-title":"Journal of Orthopaedic Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0244|cit244","first-page":"S149","article-title":"The effects of health management intervention on postmenopausal osteoporosis women treatment","volume":"23","author":"Lin","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jbmr.2216","article-title":"Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density- the CONFORS Study","volume":"29","author":"Muschitz","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0246|cit246","first-page":"S212","article-title":"Weekly alendronate plus vitamin D3 5600 IU vs. usual care: Effect on serum hydroxyvitamin D in osteoporotic postmenopausal women with vitamin D inadequacy-6-month results of a randomized trial","volume":"25","author":"Ralston","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-011-9482-4","article-title":"Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency","volume":"88","author":"Ralston","year":"2011","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0248|cit248","first-page":"S238","article-title":"Correlations between 25(OH)D and bmd change in postmenopausal osteoporotic women: Secondary analyses of a 1-year trial of weekly alendronate (ALN) plus vitamin D<inf>3<\/inf> 5600 iu vs. standard care","volume":"23","author":"Reginster","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0249|cit249","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00198-011-1721-z","article-title":"Impact of bone turnover markers and\/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/JCD:5:1:027","article-title":"Effect of two forms of alendronate administration upon bone mass after two years of treatment","volume":"5","author":"Sosa","year":"2002","journal-title":"Journal of Clinical Densitometry"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","article-title":"Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women","volume":"103","author":"Stock","year":"1997","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause (New York, N.Y.)"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1210\/jc.2010-2855","article-title":"The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density","volume":"96","author":"Fitzpatrick","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2302\/kjm.52.113","article-title":"Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis","volume":"52","author":"Iwamoto","year":"2003","journal-title":"Keio Journal of Medicine"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0256|cit256","first-page":"S750","article-title":"Overlapping and follow-up of alendronate to teriparatide treatment results in maintenance of excess BMD gain","volume":"23","author":"Fahrleitner-Pammer","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0257|cit257","unstructured":"Koziol M A shadow was cast on a bone researcher\u2019s work. What are journals doing about his papers? Retraction Watch"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1037\/h0087425","article-title":"The p-value fallacy and how to avoid it","volume":"57","author":"Dixon","year":"2003","journal-title":"Canadian Journal of Experimental Psychology"},{"key":"10.1002\/14651858.CD001155.pub3-BIB0260|cit260","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated August 2022). Cochrane, 2022 Available from: training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-013-2576-2","article-title":"Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis","volume":"25","author":"Tadrous","year":"2014","journal-title":"Osteoporosis International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD001155.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-013-2575-3","article-title":"Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis","volume":"25","author":"Lee","year":"2014","journal-title":"Osteoporosis International"},{"issue":"12","key":"10.1002\/14651858.CD001155.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","article-title":"Risk of atrial fibrillation with use of oral and intravenous bisphosphonates","volume":"113","author":"Sharma","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001155.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocrine Practice"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:34:04Z","timestamp":1788546844000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001155.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":266,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001155.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}